Literature DB >> 19296046

CSF neurofilament protein analysis in the differential diagnosis of ALS.

Thierry S Reijn1, Wilson F Abdo, Helenius J Schelhaas, Marcel M Verbeek.   

Abstract

BACKGROUND: Cerebrospinal fluid (CSF) biomarkers have been studied to differentiate between patients with ALS and neurological controls, but not in comparison to clinically more relevant disorders mimicking ALS.
METHODS: In this retrospective study, CSF concentrations of various brain-specific proteins were analyzed in patients with ALS (n = 32) and ALS-mimic disorders (n = 26).
RESULTS: CSF concentrations of neurofilament light (NFL) and heavy chain (NFHp35), but not other brain-specific proteins, were significantly higher in patients with ALS than in patients with an ALS-mimic disorder, however with maximum sensitivity or specificity of 80%. The mean CSF level of NFHp35 was 781 ng/L in the ALS group vs. 338 ng/L in the ALS-mimic disorders group and for NFL the mean CSF levels were 62 ng/L vs. 24 ng/L.
CONCLUSION: Although CSF concentrations of NFL and NFHp35 are higher in patients with ALS, the diagnostic accuracy for differentiating ALS from ALS-mimic disorders seems insufficient. Our results suggest that, in the clinical work-up of patients suspected of ALS, application of CSF analysis alone is limited but may have potential in combination with other clinical and electrophysiological markers.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19296046     DOI: 10.1007/s00415-009-0131-z

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  18 in total

Review 1.  El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis.

Authors:  B R Brooks; R G Miller; M Swash; T L Munsat
Journal:  Amyotroph Lateral Scler Other Motor Neuron Disord       Date:  2000-12

2.  A specific ELISA for measuring neurofilament heavy chain phosphoforms.

Authors:  A Petzold; G Keir; A J E Green; G Giovannoni; E J Thompson
Journal:  J Immunol Methods       Date:  2003-07       Impact factor: 2.303

3.  CSF analysis differentiates multiple-system atrophy from idiopathic late-onset cerebellar ataxia.

Authors:  W F Abdo; B P C van de Warrenburg; M Munneke; W J A van Geel; B R Bloem; H P H Kremer; M M Verbeek
Journal:  Neurology       Date:  2006-08-08       Impact factor: 9.910

4.  Decreased CSF-beta-amyloid 42 in Alzheimer's disease and amyotrophic lateral sclerosis may reflect mismetabolism of beta-amyloid induced by disparate mechanisms.

Authors:  Magnus Sjögren; Pia Davidsson; Anders Wallin; Ann-Kathrine Granérus; Eva Grundström; Håkan Askmark; Eugeen Vanmechelen; Kaj Blennow
Journal:  Dement Geriatr Cogn Disord       Date:  2002       Impact factor: 2.959

5.  Axonal damage markers in cerebrospinal fluid are increased in ALS.

Authors:  J Brettschneider; A Petzold; S D Süssmuth; A C Ludolph; H Tumani
Journal:  Neurology       Date:  2006-03-28       Impact factor: 9.910

6.  Elevated neurofilament levels in neurological diseases.

Authors:  Niklas Norgren; Lars Rosengren; Torgny Stigbrand
Journal:  Brain Res       Date:  2003-10-10       Impact factor: 3.252

Review 7.  Transgenic mouse models of amyotrophic lateral sclerosis.

Authors:  Jean-Pierre Julien; Jasna Kriz
Journal:  Biochim Biophys Acta       Date:  2006-04-21

Review 8.  Molecular and cellular pathways of neurodegeneration in motor neurone disease.

Authors:  P J Shaw
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-08       Impact factor: 10.154

9.  Tau protein concentrations in cerebrospinal fluid of patients with amyotrophic lateral sclerosis.

Authors:  F J Jiménez-Jiménez; A Hernánz; S Medina-Acebrón; F de Bustos; J M Zurdo; H Alonso; I Puertas; B Barcenilla; Y Sayed; F Cabrera-Valdivia
Journal:  Acta Neurol Scand       Date:  2005-02       Impact factor: 3.209

10.  Amyotrophic lateral sclerosis: disease stage related changes of tau protein and S100 beta in cerebrospinal fluid and creatine kinase in serum.

Authors:  Sigurd D Süssmuth; Hayrettin Tumani; Daniel Ecker; Albert C Ludolph
Journal:  Neurosci Lett       Date:  2003-12-15       Impact factor: 3.046

View more
  25 in total

1.  CSF neurofilament proteins as diagnostic and prognostic biomarkers for amyotrophic lateral sclerosis.

Authors:  Daniela Rossi; Paolo Volanti; Liliana Brambilla; Tiziana Colletti; Rossella Spataro; Vincenzo La Bella
Journal:  J Neurol       Date:  2018-01-10       Impact factor: 4.849

Review 2.  TDP-43 and Cytoskeletal Proteins in ALS.

Authors:  Moritz Oberstadt; Joseph Claßen; Thomas Arendt; Max Holzer
Journal:  Mol Neurobiol       Date:  2017-05-02       Impact factor: 5.590

Review 3.  Clinical Trial Designs in Amyotrophic Lateral Sclerosis: Does One Design Fit All?

Authors:  Katharine A Nicholson; Merit E Cudkowicz; James D Berry
Journal:  Neurotherapeutics       Date:  2015-04       Impact factor: 7.620

Review 4.  Fluid-Based Biomarkers for Amyotrophic Lateral Sclerosis.

Authors:  Lucas T Vu; Robert Bowser
Journal:  Neurotherapeutics       Date:  2017-01       Impact factor: 7.620

5.  Combination of neurofilament heavy chain and complement C3 as CSF biomarkers for ALS.

Authors:  Jeban Ganesalingam; Jiyan An; Christopher E Shaw; Gerry Shaw; David Lacomis; Robert Bowser
Journal:  J Neurochem       Date:  2011-03-21       Impact factor: 5.372

Review 6.  Amyotrophic Lateral Sclerosis: Current Status in Diagnostic Biomarkers.

Authors:  Katerina Kadena; Panayiotis Vlamos
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

Review 7.  ALS biomarkers for therapy development: State of the field and future directions.

Authors:  Michael Benatar; Kevin Boylan; Andreas Jeromin; Seward B Rutkove; James Berry; Nazem Atassi; Lucie Bruijn
Journal:  Muscle Nerve       Date:  2015-12-29       Impact factor: 3.217

Review 8.  Neurofilaments in disease: what do we know?

Authors:  Brian A Gordon
Journal:  Curr Opin Neurobiol       Date:  2020-03-06       Impact factor: 6.627

9.  Metabolite Profiling Reveals Predictive Biomarkers and the Absence of β-Methyl Amino-l-alanine in Plasma from Individuals Diagnosed with Amyotrophic Lateral Sclerosis.

Authors:  Michael S Bereman; Kaylie I Kirkwood; Tharani Sabaretnam; Sarah Furlong; Dominic B Rowe; Gilles J Guillemin; Allyson L Mellinger; David C Muddiman
Journal:  J Proteome Res       Date:  2020-06-02       Impact factor: 4.466

Review 10.  Biomarkers in amyotrophic lateral sclerosis: opportunities and limitations.

Authors:  Robert Bowser; Martin R Turner; Jeremy Shefner
Journal:  Nat Rev Neurol       Date:  2011-10-11       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.